• Search
      • Search Interactions Search Categories
    • Browse
      • Browse Categories Browse Sources
    • Information
      • About Publications Interaction Types & Directionalities Interaction Score & Query Score API Documentation FAQ Known Data Clients News Contact
    • Downloads
      • Data Source Code

QUETIAPINE Drug Record

  • Summary
  • Interactions
  • Claims
  • QUETIAPINE chembl:CHEMBL716 Approved

    Alternate Names:

    ZALURON XL
    PSYQUET XL
    SEROQUEL XL
    MINTRELEQ XL
    QUETIAPINE
    BIQUELLE XL
    EBESQUE XL
    SEOTIAPIM XL
    SONDATE XL
    BRANCICO XL
    TENPROLIDE XL
    SEROQUEL
    ATROLAK XL
    2-[2-(4-DIBENZO[B,F][1,4]THIAZEPIN-11-YL-1-PIPERAZINYL)ETHOXY]ETHANOL
    ZM-204636
    QUETIAPINE FUMARATE
    ICI 204636
    SEROQUEL®
    2-[2-(4-{2-THIA-9-AZATRICYCLO[9.4.0.0^{3,8}]PENTADECA-1(11),3(8),4,6,9,12,14-HEPTAEN-10-YL}PIPERAZIN-1-YL)ETHOXY]ETHAN-1-OL
    ZD5077
    QUETIAPINE HEMIFUMARATE
    QUETIAPINUM
    QUETIAPINA
    rxcui:51272
    pubchem.compound:5002
    drugbank:01224
    chembl:CHEMBL716
    chemidplus:111974-69-7

    Drug Info:

    Year of Approval 1997
    Drug Class antipsychotic agents
    Drug Class Small Molecule
    Drug Indications antipsychotic agent,antidepressant
    FDA Approval approved
    (2 More Sources)

    Publications:

    Thümmler S et al., 2018, Pharmacoresistant Severe Mental Health Disorders in Children and Adolescents: Functional Abnormalities of Cytochrome P450 2D6., Front Psychiatry
    Stephan PL et al., 2006, Adverse drug reactions following nonresponse in a depressed patient with CYP2D6 deficiency and low CYP 3A4/5 activity., Pharmacopsychiatry
    Nasrallah, 2008, Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles., Mol. Psychiatry
    Cabaleiro T et al., 2015, Pharmacogenetics of quetiapine in healthy volunteers: association with pharmacokinetics, pharmacodynamics, and adverse effects., Int Clin Psychopharmacol
    Vernaleken I et al., 2010, Dopamine D2/3 receptor occupancy by quetiapine in striatal and extrastriatal areas., Int J Neuropsychopharmacol
    Bressan RA et al., 2003, Optimizing limbic selective D2/D3 receptor occupancy by risperidone: a [123I]-epidepride SPET study., J Clin Psychopharmacol
    Tresadern G et al., 2011, Molecular properties affecting fast dissociation from the D2 receptor., Bioorg Med Chem
    Richelson et al., 2000, Binding of antipsychotic drugs to human brain receptors focus on newer generation compounds., Life Sci.
    Seeman, 2002, Atypical antipsychotics: mechanism of action., Can J Psychiatry
    Chen et al., 2002, TTD: Therapeutic Target Database., Nucleic Acids Res.
    Kapur et al., 2000, A positron emission tomography study of quetiapine in schizophrenia: a preliminary finding of an antipsychotic effect with only transiently high dopamine D2 receptor occupancy., Arch. Gen. Psychiatry
    Tauscher J et al., 2004, Equivalent occupancy of dopamine D1 and D2 receptors with clozapine: differentiation from other atypical antipsychotics., Am J Psychiatry
    Moallem N et al., 2012, Quetiapine improves response inhibition in alcohol dependent patients: a placebo-controlled pilot study., Pharmacol Biochem Behav
    López-Rodríguez R et al., 2013, Pharmacodynamic genetic variants related to antipsychotic adverse reactions in healthy volunteers., Pharmacogenomics
    McIntyre et al., 2007, A preclinical and clinical rationale for quetiapine in mood syndromes., Expert Opin Pharmacother
    Goldstein, 1999, Quetiapine fumarate (Seroquel): a new atypical antipsychotic., Drugs Today
    Yatham et al., 2005, Atypical antipsychotics in bipolar depression: potential mechanisms of action., J Clin Psychiatry
    Kim KA et al., 2014, Influence of ABCB1 and CYP3A5 genetic polymorphisms on the pharmacokinetics of quetiapine in healthy volunteers., Pharmacogenet Genomics
    Zanger UM et al., 2008, Functional pharmacogenetics/genomics of human cytochromes P450 involved in drug biotransformation., Anal Bioanal Chem
    Nurmi EL et al., 2013, Moderation of antipsychotic-induced weight gain by energy balance gene variants in the RUPP autism network risperidone studies., Transl Psychiatry
    Monteleone P et al., 2010, Endocannabinoid Pro129Thr FAAH functional polymorphism but not 1359G/A CNR1 polymorphism is associated with antipsychotic-induced weight gain., J Clin Psychopharmacol
    Tiwari AK et al., 2010, A common polymorphism in the cannabinoid receptor 1 (CNR1) gene is associated with antipsychotic-induced weight gain in Schizophrenia., Neuropsychopharmacology
    Wood et al., 2006, Pharmacological profile of antipsychotics at monoamine receptors: atypicality beyond 5-HT2A receptor blockade., CNS Neurol Disord Drug Targets
    Ichikawa et al., 2002, Atypical antipsychotic drugs, quetiapine, iloperidone, and melperone, preferentially increase dopamine and acetylcholine release in rat medial prefrontal cortex: role of 5-HT1A receptor agonism., Brain Res.
    Crisafulli C et al., 2012, Case-control association study for 10 genes in patients with schizophrenia: influence of 5HTR1A variation rs10042486 on schizophrenia and response to antipsychotics., Eur Arch Psychiatry Clin Neurosci
    Vázquez-Bourgon J et al., 2010, Serotonin transporter polymorphisms and early response to antipsychotic treatment in first episode of psychosis., Psychiatry Res
    Xu Q et al., 2016, Association studies of genomic variants with treatment response to risperidone, clozapine, quetiapine and chlorpromazine in the Chinese Han population., Pharmacogenomics J
    Drago A et al., 2014, Genome-wide association study supports the role of the immunological system and of the neurodevelopmental processes in response to haloperidol treatment., Pharmacogenet Genomics
    Opgen-Rhein C et al., 2010, Association of HTR2C, but not LEP or INSIG2, genes with antipsychotic-induced weight gain in a German sample., Pharmacogenomics
    Porcelli S et al., 2016, PDE7B, NMBR and EPM2A Variants and Schizophrenia: A Case-Control and Pharmacogenetics Study., Neuropsychobiology
    Zhang JP et al., 2016, Pharmacogenetic Associations of Antipsychotic Drug-Related Weight Gain: A Systematic Review and Meta-analysis., Schizophr Bull
    Czerwensky F et al., 2013, MC4R rs489693: a clinical risk factor for second generation antipsychotic-related weight gain?, Int J Neuropsychopharmacol
    Malhotra AK et al., 2012, Association between common variants near the melanocortin 4 receptor gene and severe antipsychotic drug-induced weight gain., Arch Gen Psychiatry
    Delacrétaz A et al., 2017, Association of variants in SH2B1 and RABEP1 with worsening of low-density lipoprotein and glucose parameters in patients treated with psychotropic drugs., Gene
  • QUETIAPINE   MIR582

    Interaction Score: 2.29

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB

  • QUETIAPINE   EIF2AK4

    Interaction Score: 0.76

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    24751813


    Sources:
    PharmGKB

  • QUETIAPINE   MC4R

    Interaction Score: 0.72

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    27217270 23920449 23799528 22566560


    Sources:
    PharmGKB

  • QUETIAPINE   EPM2A

    Interaction Score: 0.65

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    27092952


    Sources:
    PharmGKB

  • QUETIAPINE   RABEP1

    Interaction Score: 0.51

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    28694205


    Sources:
    PharmGKB

  • QUETIAPINE   SH2B1

    Interaction Score: 0.51

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    28694205


    Sources:
    PharmGKB

  • QUETIAPINE   HTR1A

    Interaction Score: 0.33

    Interaction Types & Directionality:
    partial agonist (activating)
    agonist (activating)
    antagonist (inhibitory)

    Interaction Info:

    PMIDs:
    17563257 11132243 16918396 17848919 12445705 22120873


    Sources:
    TEND PharmGKB

  • QUETIAPINE   CNR1

    Interaction Score: 0.29

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    23799528 20631561 20107430


    Sources:
    PharmGKB

  • QUETIAPINE   HTR2C

    Interaction Score: 0.27

    Interaction Types & Directionality:
    ligand
    antagonist (inhibitory)

    Interaction Info:
    Trial Name Seroquel
    Novel drug target Established target

    PMIDs:
    11132243 17848919 20504252


    Sources:
    TdgClinicalTrial TEND PharmGKB

  • QUETIAPINE   HTR2B

    Interaction Score: 0.27

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Novel drug target Established target
    Trial Name Seroquel

    PMIDs:
    None found


    Sources:
    TdgClinicalTrial TEND

  • QUETIAPINE   FAAH

    Interaction Score: 0.22

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    20631561


    Sources:
    PharmGKB

  • QUETIAPINE   DRD3

    Interaction Score: 0.18

    Interaction Types & Directionality:
    ligand
    antagonist (inhibitory)

    Interaction Info:

    PMIDs:
    17848919 25025989 20392299 12544369


    Sources:
    PharmGKB

  • QUETIAPINE   HTR2A

    Interaction Score: 0.16

    Interaction Types & Directionality:
    agonist (activating)
    antagonist (inhibitory)

    Interaction Info:
    Trial Name Seroquel
    Novel drug target Established target

    PMIDs:
    17563257 11132243 12973385 17848919 16038601


    Sources:
    TdgClinicalTrial TEND

  • QUETIAPINE   COMT

    Interaction Score: 0.14

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    26282453


    Sources:
    PharmGKB

  • QUETIAPINE   DRD2

    Interaction Score: 0.14

    Interaction Types & Directionality:
    antagonist (inhibitory)

    Interaction Info:
    Trial Name Seroquel
    Novel drug target Established target

    PMIDs:
    21421319 11132243 11873706 17848919 11752352 10839333


    Sources:
    DTC TdgClinicalTrial TEND TTD

  • QUETIAPINE   SLC6A4

    Interaction Score: 0.13

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    23859574 20031235


    Sources:
    PharmGKB

  • QUETIAPINE   GRIN2B

    Interaction Score: 0.12

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    23859574


    Sources:
    PharmGKB

  • QUETIAPINE   ADRA1B

    Interaction Score: 0.11

    Interaction Types & Directionality:
    antagonist (inhibitory)

    Interaction Info:

    PMIDs:
    11132243 17848919


    Sources:
    TEND

  • QUETIAPINE   PDE4D

    Interaction Score: 0.08

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB

  • QUETIAPINE   CYP3A5

    Interaction Score: 0.07

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    24240480 18695978


    Sources:
    PharmGKB

  • QUETIAPINE   DRD1

    Interaction Score: 0.06

    Interaction Types & Directionality:
    antagonist (inhibitory)

    Interaction Info:

    PMIDs:
    17848919 15337652 22037407


    Sources:
    TEND

  • QUETIAPINE   HRH1

    Interaction Score: 0.05

    Interaction Types & Directionality:
    antagonist (inhibitory)

    Interaction Info:

    PMIDs:
    11132243 17848919


    Sources:
    TEND

  • QUETIAPINE   RGS4

    Interaction Score: 0.02

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB

  • QUETIAPINE   CYP2D6

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    29472872 16871470


    Sources:
    PharmGKB

  • QUETIAPINE   CYP2C19

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    25025989


    Sources:
    PharmGKB

  • QUETIAPINE   CYP1A2

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    25025989


    Sources:
    PharmGKB

  • QUETIAPINE   CYP3A4

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC PharmGKB

  • TEND: QUETIAPINE

    • Version: 01-August-2011

    Alternate Names:
    QUETIAPINE Primary Drug Name

    Drug Info:
    Year of Approval 1997
    Drug Class antipsychotic agents

    Publications:

  • TdgClinicalTrial: QUETIAPINE

    • Version: January-2014

    Alternate Names:

    Drug Info:
    FDA Approval approved
    Drug Indications antipsychotic agent,antidepressant
    Drug Class Small Molecule

    Publications:

  • DTC: QUETIAPINE

    • Version: 02-September-2020

    Alternate Names:
    CHEMBL716 ChEMBL Drug ID

    Drug Info:

    Publications:
    Tresadern G et al., 2011, Molecular properties affecting fast dissociation from the D2 receptor., Bioorg Med Chem

  • PharmGKB: quetiapine

    • Version: 18-August-2020

    Alternate Names:

    Drug Info:

    Publications:
    Cabaleiro T et al., 2015, Pharmacogenetics of quetiapine in healthy volunteers: association with pharmacokinetics, pharmacodynamics, and adverse effects., Int Clin Psychopharmacol
    Drago A et al., 2014, Genome-wide association study supports the role of the immunological system and of the neurodevelopmental processes in response to haloperidol treatment., Pharmacogenet Genomics
    Monteleone P et al., 2010, Endocannabinoid Pro129Thr FAAH functional polymorphism but not 1359G/A CNR1 polymorphism is associated with antipsychotic-induced weight gain., J Clin Psychopharmacol

  • TTD: Quetiapine

    • Version: 2020.06.01

    Alternate Names:
    D0H7KF TTD Drug ID

    Drug Info:

    Publications:

  • ChemblDrugs: chembl:CHEMBL716

    • Version: ChEMBL_27

    Alternate Names:

    Drug Info:

    Publications:

Disclaimer: This resource is intended for purely research purposes. It should not be used for emergencies or medical or professional advice.

A finding of a drug-gene interaction or potentially druggable category does not necessarily indicate effectiveness (or lack thereof) of any drug or treatment regimen. A finding of no interaction or no potentially druggable category does not necessarily indicate lack of effectiveness of any drug or treatment regimen. Drug-gene interactions or potentially druggable categories are not presented in ranked order of potential or predicted efficacy.

The dgidb.org website does not provide any medical or healthcare products, services or advice, and is not for medical emergencies or urgent situations. IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY, CALL YOUR DOCTOR OR 911 IMMEDIATELY. Information contained on this website is not a substitute for a doctor's medical judgment or advice. We recommend that you discuss your specific, individual health concerns with your doctor or health care professional.

DGIdb (v4.2.0 - sha1 afd9f30b) • Last updated 2020-10-21